Open AccessImmune targeted therapy for diffuse large B cell lymphoma
Author(s) -
Yuyan Zheng,
Junqi Si,
Yuan Tian,
Sa Ding,
Chen Tian
Publication year - 2021
Publication title -
blood science
Language(s) - Uncategorized
Resource type - Journals
ISSN - 2543-6368
DOI - 10.1097/bs9.0000000000000095
Subject(s) - vincristine , rituximab , lymphoma , medicine , prednisone , diffuse large b cell lymphoma , immune system , cyclophosphamide , oncology , targeted therapy , immunology , cancer research , chemotherapy , cancer
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is highly heterogeneous and invasive. Although the majority of DLBCL patients show a good response to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment, approximately one-third of patients still have a poor prognosis. Many immune-targeted drugs, such as bispecific T-cell engagers and CAR T-cell therapy, have been proven effective for refractory and relapsed patients. This article reviews the progress of immune targeted therapy for DLBCL.